New Zealand markets closed

Belite Bio, Inc (BLTE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
49.16+0.21 (+0.43%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close48.95
Open49.11
Bid49.11 x 100
Ask49.69 x 100
Day's range48.80 - 49.30
52-week range13.55 - 50.15
Volume18,443
Avg. volume54,700
Market cap1.465B
Beta (5Y monthly)-1.48
PE ratio (TTM)N/A
EPS (TTM)-1.13
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est56.50
  • GlobeNewswire

    Belite Bio to Present at the JonesHealthcare Seaside Summit

    SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will participate in the JonesHealthcare Seaside Summit in Encinitas, CA, and present a corporate update on Monday, July 15, 2024, at 1:00 pm PT. A webcast of the

  • Simply Wall St.

    Estimating The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)

    Key Insights Belite Bio's estimated fair value is US$51.94 based on 2 Stage Free Cash Flow to Equity With US$49.96...

  • GlobeNewswire

    Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

    Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics (aged ≤18 years) (p<0.001)In the Phase 2 trial,